相似文献
1
Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.
Life Sci. 2008 Apr 9;82(15-16):855-61. doi: 10.1016/j.lfs.2008.01.019. Epub 2008 Feb 14.
2
Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.
Peptides. 2011 Aug;32(8):1677-84. doi: 10.1016/j.peptides.2011.06.011. Epub 2011 Jun 25.
3
ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.
Peptides. 2015 Feb;64:55-61. doi: 10.1016/j.peptides.2014.12.005. Epub 2014 Dec 30.
4
AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists.
Front Endocrinol (Lausanne). 2017 Jul 21;8:176. doi: 10.3389/fendo.2017.00176. eCollection 2017.
5
Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells.
Eur J Pharmacol. 2003 Aug 1;474(1):21-9. doi: 10.1016/s0014-2999(03)01996-4.
6
In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors.
J Pharmacol Exp Ther. 2006 Sep;318(3):1265-72. doi: 10.1124/jpet.106.104141. Epub 2006 Jun 9.
7
A bombesin receptor subtype-3 peptide increases nuclear oncogene expression in a MEK-1 dependent manner in human lung cancer cells.
Eur J Pharmacol. 2001 Jan 19;412(1):13-20. doi: 10.1016/s0014-2999(00)00941-9.
8
A structure function study of C-terminal extensions of bombesin.
Peptides. 1991 Sep-Oct;12(5):1149-51. doi: 10.1016/0196-9781(91)90072-w.
9
Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3.
J Biol Chem. 1998 May 29;273(22):13613-24. doi: 10.1074/jbc.273.22.13613.
10
Discovery of potent and selective peptide agonists at the GRP-preferring bombesin receptor (BB2).
J Pept Sci. 2001 Nov;7(11):598-605. doi: 10.1002/psc.359.
引用本文的文献
1
Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress.
Bioengineering (Basel). 2025 Apr 30;12(5):481. doi: 10.3390/bioengineering12050481.
2
Synthesis and Evaluation of a Monomethyl Auristatin E─Integrin αβ Binding Peptide-Drug Conjugate for Tumor Targeted Drug Delivery.
J Med Chem. 2023 Jul 27;66(14):9842-9852. doi: 10.1021/acs.jmedchem.3c00631. Epub 2023 Jul 7.
3
Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.
Front Endocrinol (Lausanne). 2021 Sep 1;12:728088. doi: 10.3389/fendo.2021.728088. eCollection 2021.
4
Peptide receptors as cancer drug targets.
Ann N Y Acad Sci. 2019 Nov;1455(1):141-148. doi: 10.1111/nyas.14100. Epub 2019 May 10.
5
Anti-Proliferation Activity of a Decapeptide from toward Human Lung Cancer H1299 Cells.
Mar Drugs. 2019 Feb 18;17(2):122. doi: 10.3390/md17020122.
6
Neuropeptide G Protein-Coupled Receptors as Oncotargets.
Front Endocrinol (Lausanne). 2018 Jun 29;9:345. doi: 10.3389/fendo.2018.00345. eCollection 2018.
7
Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.
Biomedicines. 2016 May 26;4(2):11. doi: 10.3390/biomedicines4020011.
8
Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.
Expert Opin Ther Targets. 2016 Sep;20(9):1055-73. doi: 10.1517/14728222.2016.1164694. Epub 2016 Mar 28.
9
Insights into bombesin receptors and ligands: Highlighting recent advances.
Peptides. 2015 Oct;72:128-44. doi: 10.1016/j.peptides.2015.04.026. Epub 2015 May 11.
10
Scorpion peptides: potential use for new drug development.
J Toxicol. 2013;2013:958797. doi: 10.1155/2013/958797. Epub 2013 Jun 15.
本文引用的文献
1
Radiolabelled regulatory peptides for imaging and therapy.
Anticancer Agents Med Chem. 2007 May;7(3):345-57. doi: 10.2174/187152007780618171.
2
A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells.
Int J Oncol. 2007 Jun;30(6):1453-9.
3
Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.
Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1228-38. doi: 10.1007/s00259-006-0356-3. Epub 2007 Feb 8.
4
Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells.
Cell Mol Life Sci. 2006 Oct;63(19-20):2377-86. doi: 10.1007/s00018-006-6264-7.
5
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10403-10407. doi: 10.1073/pnas.0602971103. Epub 2006 Jun 26.
6
In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors.
J Pharmacol Exp Ther. 2006 Sep;318(3):1265-72. doi: 10.1124/jpet.106.104141. Epub 2006 Jun 9.
7
Marine peptides and related compounds in clinical trial.
Anticancer Agents Med Chem. 2006 Jan;6(1):33-40. doi: 10.2174/187152006774755519.
8
Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents.
J Am Chem Soc. 2005 Dec 21;127(50):17667-71. doi: 10.1021/ja053663v.
9
Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy.
Curr Pharm Des. 2005;11(9):1167-80. doi: 10.2174/1381612053507594.
10
Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells.
J Biol Chem. 2004 May 28;279(22):23580-9. doi: 10.1074/jbc.M401938200. Epub 2004 Mar 11.
Zotero 插件